NG,NG-Dimethylarginine dihydrochloride
NG,NG-Dimethylarginine dihydrochloride is a reversible inhibitor of nitric oxide synthetase in vivo and in vitro.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Molecules2021, 26(1),230
Food Chem Toxicol.2023, 176:113785.
J Agric Food Chem.2019, 67(27):7748-7754
Nat Commun.2023, 14(1):5075.
Food Chem.2019, 279:80-87
Front Immunol.2020, 11:598556.
Drug Chem Toxicol.2020, 1-12.
Pharmaceutics.2020, 12(9):845.
American Association for Anatomy2020, doi: 10.1002.
Phytomedicine.2018, 38:12-23
Related and Featured Products
Lancet. 1992 Mar 7;339(8793):572-5.
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.[Pubmed:
1347093]
Nitric oxide (NO), synthesised from L-arginine, contributes to the regulation of blood pressure and to host defence.
METHODS AND RESULTS:
We describe in-vitro and in-vivo evidence that NO synthesis can be inhibited by an endogenous compound, NG,NG-dimethylarginine (asymmetrical dimethylarginine, ADMA). In man, this inhibitor is found in plasma and more than 10 mg is excreted in urine over 24 h. However, in patients with end-stage chronic renal failure, who have little or no urine output, elimination is blocked and circulating concentrations of the inhibitor rise sufficiently to inhibit NO synthesis.
CONCLUSIONS:
Accumulation of endogenous ADMA, leading to impaired NO synthesis, might contribute to the hypertension and immune dysfunction associated with chronic renal failure.
